Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1

Journal of Virology

Volumn 70, Issue 8, 1996, Pages 5642-5645

  Quan, Yudong ^a   Gu, Zhengxian ^a   Li, Xuguang ^a   Li, Zhuo ^a   Morrow, Casey D ^b   Wainberg, Mark A ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 3' THIACYTIDINE TRIPHOSPHATE; 2',3' DIDEOXYADENOSINE TRIPHOSPHATE; 2',3' DIDEOXYCYTIDINE 5' TRIPHOSPHATE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; DNA DIRECTED DNA POLYMERASE; MUTANT PROTEIN; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION;

EID: 0029896847     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.8.5642-5645.1996     Document Type: Article

References (24)

1. Allain, B., M. Lapadat-Tapolsky, C. Berlioz, and J. L. Darlix. 1994. Transactivation of the minus-strand DNA transfer by nucleocapsid protein during reverse transcription of the retroviral genome. EMBO J. 13:973-981.
2. Lys3 as primers in an endogenous human immunodeficiency virus-t in vitro reverse transcription/template-switching reaction. J. Biol. Chcm. 269:14672-14680.
3. Borrolo-Esoda, K., and L. R. Boone. 1994. Development of a human immunodeficiency virus-1 in vitro DNA synthesis system to study reverse transcriptase inhibitors. Antiviral Res. 23:235-249.
4. Boyer, P. L., A. L Ferris, and S. H. Hughes. 1992. Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1. J. Virol. 66:1031-1039.
5. Boyer, P. L., and S. H. Hughes. 1995. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39:1624-1628.
6. Chameau, P., M. Alizon, and F. Clavel. 1992. A second origin of plus-strand synthesis is required for optimal human immunodeficiency virus replication. J. Virol. 66:2814-2820.
7. Darlix, J. L., C. Gabus, M.-T. Nugeyre, F. Clavel, and F. Barré-Sinoussi. 1990. Cis elements and trans-acting factors involved in the tRNA dimerization of the human immunodeficiency virus HIV-1. J. Mol. Biol. 216:689-699.
8. Debyser, Z., A.-M. Vandamme, R. Pauwels, M. Baba, J. Desmyter, and E. De Clercq. 1992. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2′,3′-dideoxynucleoside 5′-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-(phenylthio)thymine derivatives. J. Biol. Chem. 267:11769-11776.
9. Faraj, A., L. A. Agrofoglio, J. K. Wakefield, S. Mcpherson, C. D. Morrow, G. Gosselin, C. Marthe, J.-L. Imbach, R. F. Schinazi, and J.-F. Sommadossi. 1994. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5′-triphosphate β enantiomers of cytidine analogs. Antimicrob. Agents Chemother. 38:2300-2305.
10. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
11. Gilboa, E., S. Goff, A. Shields, F. Yoshimura, S. Mitra, and D. Baltimore. 1979. In vitro synthesis of a 9 kbp terminally redundant DNA carrying the infectivity of Moloncy murine leukemia virus. Cell 16:863-874.
12. Gu, Z., E. J. Arts, M. A. Parniak, and M. A. Wainberg. 1995. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2′3′-dideoxycytidine 5′ triphosphate and other drugs. Proc. Natl. Acad. Sci. USA 92:2760-2764.
13. Gu, Z., R. S. Fletcher, E. J. Arts, M. A. Wainberg, and M. A. Parniak. 1994. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J. Biol. Chem. 269:28118-28122.
14. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J. Virol. 66:7128-7135.
15. Hermann, T., T. Meier, M. Gotte, and H. Heumann. 1994 The "helix clamp" in HIV-1 reverse transcriptase: a new nucleic acid binding motif common in nucleic acid polymerases. Nucleic Acids Res. 22:4625-4633.
16. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1912. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
17. Lacey, S. F., J. E. Reardon, E. S. Furfine, T. A. Kunkel, K. Bebenek, K. A. Eckert, S. D. Kemp, and B. A. Larder. 1992. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J. Biol. Chem. 267: 15789-15794.
18. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
19. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
20. Martin, J. L., J. E. Wilson, R. L. Haynes, and P. A. Furman. 1993. Mechanism of resistance of human immunodeficiency virus type 1 to 2′,3′-dideoxyinosine. Proc. Natl. Acad. Sci. USA 90:6135-6139.
21. Schinazi, R. F., R. M. Lloyd, Jr., M.-H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine analogs. Antimicrob. Agents Chemother. 37:875-881.
22. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
23. Trono, D. 1992. Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J. Virol. 66:4893-4900.
24. Wakefield, J. K., S. A. Jablonski, and C. D. Morrow. 1992. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J. Virol. 66:6806-6812.